Piper Sandler Reiterates Overweight on Amphastar Pharma, Maintains $71 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has reiterated an Overweight rating on Amphastar Pharma (NASDAQ:AMPH) and maintained a price target of $71.
June 27, 2024 | 3:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst David Amsellem has reiterated an Overweight rating on Amphastar Pharma and maintained a price target of $71.
The reiteration of an Overweight rating and a maintained price target of $71 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100